Eton Pharmaceuticals, Inc. (ETON) stock
ETONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30524% above fair value
$61.99−1.66 (-2.61%)
Close on Nov 18, 2026Market cap $1.77BP/E 158.9Yield –
Eton Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Eton Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was $16.31M. For fiscal 2025 it was -$844.00K. The highest annual figure on record is -$844.00K in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$844.00K | – |
| FY2024 | Dec 31, 2024 | -$2.60M | – |
| FY2023 | Dec 31, 2023 | -$1.19M | – |
| FY2022 | Dec 31, 2022 | -$8.26M | – |
| FY2021 | Dec 31, 2021 | -$1.50M | – |
| FY2020 | Dec 31, 2020 | -$27.11M | – |
| FY2019 | Dec 31, 2019 | -$18.60M | – |
| FY2018 | Dec 31, 2018 | -$10.32M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $12.79M | – |
| Q1 FY2026 | Mar 31, 2026 | $2.41M | – |
| Q4 FY2025 | Dec 31, 2025 | $2.46M | +291.7% |
| Q3 FY2025 | Sep 30, 2025 | -$1.36M | -367.8% |
| Q2 FY2025 | Jun 30, 2025 | -$1.48M | – |
| Q1 FY2025 | Mar 31, 2025 | -$470.00K | – |
| Q4 FY2024 | Dec 31, 2024 | $629.00K | – |
| Q3 FY2024 | Sep 30, 2024 | $509.00K | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.94M | -175.6% |
| Q1 FY2024 | Mar 31, 2024 | -$800.00K | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.99M | -287.7% |
| Q3 FY2023 | Sep 30, 2023 | -$548.00K | – |
| Q2 FY2023 | Jun 30, 2023 | $3.88M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.53M | – |
| Q4 FY2022 | Dec 31, 2022 | $1.06M | -19.2% |
| Q3 FY2022 | Sep 30, 2022 | -$2.90M | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.34M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.09M | -194.9% |
| Q4 FY2021 | Dec 31, 2021 | $1.31M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.85M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.33M | – |
| Q1 FY2021 | Mar 31, 2021 | $5.36M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.42M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.27M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.54M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.88M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.66M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.04M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.35M | – |
| Q1 FY2019 | Mar 31, 2019 | -$7.55M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.29M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.37M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.70M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.96M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.77M | – |
See a number that looks wrong?